SBIR Phase II: Improved Maternal Health with Predictive Patient Monitoring

SBIR 第二阶段：通过预测性患者监测改善孕产妇健康

• 批准号: 2233743
• 负责人: Courtney Williams
• 金额: $ 97.5万
• 依托单位: Emagine Solutions Technology
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-15 至 2025-11-30
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2233743&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Improved; Maternal

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to develop further a predictive model for health providers to address the life-threatening condition of preeclampsia in pregnant and postpartum patients. Preeclampsia affects 1 in 20 births, or 150,000 women in the U.S. each year. Not only does Preeclampsia cost 70,000 lives globally each year, it is also an expensive burden for healthcare systems. It costs nearly three times more to treat a patient with preeclampsia than one without this complication. When deployed at scale, the technology proposed in this SBIR grant could be a key factor to reducing maternal mortality in the United States, improving obstetric patient outcomes, reducing the cost of obstetric care, and helping to reduce health disparities.The proposed project will research and develop a method to potentially detect preeclampsia. Preeclampsia is a hypertensive disorder of pregnancy. This dangerous condition also costs the U.S. healthcare system $2.18 billion per year or one-third of the total amount spent on maternal healthcare in our country. Research objectives include optimizing a machine learning model, integrating patient-facing software into Electronic Health Records systems, implementing the predictive model for preeclampsia, integrating with peripheral wellness devices, developing reminder notification mechanisms, determining appropriate interface enhancements, and defining commercialization and regulatory strategies. Improving maternal health outcomes advances the general health and welfare of American families and can improve our country’s economic competitiveness on the world stage.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业创新研究（SBIR）第二阶段项目的更广泛的影响/商业潜力是为医疗服务提供者进一步开发预测模型，以解决妊娠和产后患者先兆子痫的危及生命的状况。先兆子痫影响20个新生儿中的1个，即美国每年有150，000名妇女。先兆子痫不仅每年在全球造成7万人死亡，而且对医疗保健系统来说也是一个昂贵的负担。 治疗先兆子痫患者的费用比没有这种并发症的患者高出近三倍。当大规模部署时，SBIR赠款中提出的技术可能是降低美国孕产妇死亡率的关键因素，改善产科患者的结局，降低产科护理成本，并有助于减少健康差距。拟议的项目将研究和开发一种可能检测先兆子痫的方法。先兆子痫是一种妊娠期高血压疾病。这种危险的情况也花费了美国医疗保健系统每年21.8亿美元，占我国孕产妇医疗保健总支出的三分之一。研究目标包括优化机器学习模型，将面向患者的软件集成到电子健康记录系统中，实施先兆子痫的预测模型，与外围健康设备集成，开发提醒通知机制，确定适当的界面增强，以及定义商业化和监管策略。 改善孕产妇健康结果促进了美国家庭的总体健康和福利，并可以提高我国在世界舞台上的经济竞争力。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。